The National Institute on Aging (NIA), part of the NIH, awarded the grant to develop an Alzheimer’s disease therapeutic.
Aphios will collaborate with Louisiana State University Health Sciences Center, which will conduct in vitro and in vivo efficacy, toxicity and pharmacokinetic studies in triple transgenic AD mice.
Aphios president and CEO Trevor Castor said they are developing novel formulations of APH-0703 based on Aphios’ proprietary hydrophobic-based formulation and patented SFS-PNS polymer nanospheres technologies.